Hubbry Logo
PEG 400PEG 400Main
Open search
PEG 400
Community hub
PEG 400
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
PEG 400
PEG 400
from Wikipedia
Polyethylene glycol
Polyethylene glycol
Polyethylene glycol
Names
IUPAC name
Polyethylene glycol
Identifiers
ChemSpider
  • none
UNII
Properties
C2nH4n+2On+1, n = 8.2 to 9.1
Molar mass 380-420 g/mol
Density 1.128 g/cm3
Melting point 4 to 8 °C (39 to 46 °F; 277 to 281 K)
Viscosity 90.0 cSt at 25 °C, 7.3 cSt at 99 °C
Hazards
Flash point 238 °C (460 °F; 511 K)
Lethal dose or concentration (LD, LC):
30 mL/kg, orally in rats
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)

PEG 400 (polyethylene glycol 400) is a low-molecular-weight grade of polyethylene glycol. It is a clear, colorless, viscous liquid. Due in part to its low toxicity, PEG 400 is widely used in a variety of pharmaceutical formulations.

Chemical properties

[edit]

PEG 400 is strongly hydrophilic. The partition coefficient of PEG 400 between hexane and water is 0.000015 (log), indicating that when PEG 400 is mixed with water and hexane, there are only 15 parts of PEG400 in the hexane layer per 1 million parts of PEG 400 in the water layer.[1]

PEG 400 is soluble in water, acetone, alcohols, benzene, glycerin, glycols, and aromatic hydrocarbons. It is not miscible with aliphatic hydrocarbons nor diethyl ether. Therefore, reaction products can be extracted from the reaction media with those solvents.

References

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia
from Grokipedia
Polyethylene glycol 400 (PEG 400) is a synthetic, low-molecular-weight polyether compound composed of repeating units of , with an average molecular weight of approximately 400 daltons. It is produced through the anionic of using or as an initiator and an alkaline catalyst such as . This results in a clear, colorless, that is highly hydrophilic, miscible with , and soluble in many organic solvents like and acetone, but insoluble in non-polar solvents such as hydrocarbons. In pharmaceuticals, PEG 400 functions primarily as an , serving as a , solubilizer, , and in various including oral capsules, topical ointments, and ophthalmic solutions. It enhances the of poorly soluble drugs by improving their dissolution and is commonly incorporated into , such as those for dry eye relief, where it acts as a lacrimomimetic to lubricate the ocular surface and stabilize the tear film. Additionally, PEG 400 is utilized in as a , emollient, and carrier for active ingredients, helping to retain moisture in formulations like creams, lotions, and shampoos. In the , it is approved as a direct additive for uses such as a binder, , , and stabilizer in various applications including food tablets and nonnutritive sweeteners in accordance with FDA regulations for polyethylene glycols with mean molecular weights between 200 and 9,500. PEG 400 is characterized by low , with oral absorption typically less than 0.5% in humans, and it is considered biologically inert and safe for approved applications by regulatory bodies including the U.S. (FDA). Its poor systemic absorption minimizes potential risks, though high oral doses may cause gastrointestinal effects like osmotic . Overall, its and versatility have made it a staple in medical, cosmetic, and industrial products since its commercial development in the mid-20th century.

Overview

Definition and Nomenclature

PEG 400 is a synthetic polyether compound derived from the of , characterized by an average molecular weight ranging from 380 to 420 g/mol, which corresponds to an with approximately 8 to 9 repeating units in the general formula H(OCH₂CH₂)_nOH. The term "PEG" is an abbreviation for , a family of hydrophilic polymers where the numeric suffix, such as "400," denotes the approximate average molecular weight in daltons, reflecting the and polydispersity of the chain lengths. This naming convention differentiates PEG 400 from higher-molecular-weight variants like PEG 3350, which features longer chains (n ≈ 75-76) and a solid, waxy physical state at , in contrast to the form of PEG 400 due to its shorter chain length. Polyethylene glycols, including PEG 400, were first synthesized in laboratory settings in 1929 by Staudinger and Schweitzer through the anionic of , with commercial-scale production emerging in the 1930s via base-catalyzed processes developed by companies such as . PEG 400 gained prominence in industrial applications following , leveraging its and low for formulation purposes.

Physical Characteristics

PEG 400 appears as a clear, colorless to slightly viscous liquid at . It has a of 1.12–1.14 g/cm³ at 20°C. The material exhibits a of approximately 90 mPa·s at 25°C, contributing to its flow characteristics in liquid form. The of PEG 400 ranges from 4–8°C, allowing it to remain liquid under typical ambient conditions. Its exceeds 250°C, though the compound decomposes prior to reaching a true boiling state. PEG 400 is hygroscopic, readily absorbing from the atmosphere, which helps maintain its in contrast to higher molecular weight polyethylene glycols that solidify. The substance is nearly odorless with a mild scent. It possesses a slightly taste.

Chemical Properties

Molecular Structure

PEG 400, or with an average molecular weight of approximately 400 Da, is represented by the H(OCH₂CH₂)_nOH, where n denotes the average around 9. This formula reflects its composition as a linear consisting of repeating units, –CH₂CH₂O–, capped at both ends by hydroxyl groups, forming a flexible chain that imparts hydrophilic character due to the polar linkages and terminal alcohols. Unlike a discrete , PEG 400 exists as a polydisperse , encompassing a distribution of oligomeric chains with varying lengths centered around the 400 Da average, typically characterized by a polydispersity index (PDI) of 1.1 to 1.2. This heterogeneity arises from the process and is routinely confirmed through techniques such as (GPC), which separates chains by hydrodynamic volume to reveal the molecular weight distribution. PEG 400 is derived from the of monomer (C₂H₄O), but as the hydrated polymer, it incorporates to form the extended polyether backbone, distinguishing it from the cyclic precursor.

and Stability

PEG 400 exhibits high in a variety of polar solvents due to its hydrophilic polyether chain structure. It is infinitely miscible with , allowing for the formation of clear aqueous solutions without or . Additionally, PEG 400 is very soluble in , acetone, and , which facilitates its use in mixed solvent systems for pharmaceutical formulations. In contrast, it shows limited solubility in non-polar solvents, being only partially soluble in aromatic hydrocarbons and practically insoluble in aliphatic hydrocarbons and mineral oils. Thermally, PEG 400 demonstrates good stability up to temperatures of 150–200°C, with low volatility that prevents significant under standard processing conditions. At higher temperatures exceeding 200°C, occurs, primarily yielding and as degradation products through chain scission and mechanisms. This decomposition is more pronounced in dry conditions, where oxidative processes can accelerate breakdown even at moderately elevated temperatures around 75°C. Chemically, PEG 400 is resistant to under neutral and mildly acidic or basic conditions, maintaining integrity across a range of 4–10 without significant degradation. It remains stable in the presence of dilute acids and bases, but exposure to strong oxidants, such as potassium periodate in alkaline media, can lead to oxidation of the terminal hydroxyl groups, forming long-chain aldehydes and minor amounts of carboxylic acids. This oxidative vulnerability underscores the need for antioxidants in formulations prone to aerial exposure. As a hygroscopic , PEG 400 readily absorbs from humid environments via hydrogen bonding with its terminal hydroxyl groups and oxygens, which helps preserve its liquid state and prevents even at high relative humidities. This property contributes to its stability in aqueous or semi-aqueous systems, where it forms stable solutions without phase changes under typical storage conditions.

Production

Synthesis Process

PEG 400 is synthesized through the of using or as the initiator. In this process, , a cyclic , undergoes nucleophilic attack by the hydroxide ion derived from , leading to the formation of a linear with hydroxyl end groups. The reaction is typically conducted in the presence of an acidic or basic catalyst to facilitate the , with basic catalysts such as being commonly employed for producing low molecular weight PEGs. The fundamental reaction can be represented by the simplified equation: n\ceCH2CH2O+\ceH2O\ceH(OCH2CH2)nOHn \ce{CH2-CH2O} + \ce{H2O} \rightarrow \ce{H-(OCH2CH2)_n-OH} where nn averages around 9 for PEG 400, corresponding to a molecular weight of approximately 400 Da. This polymerization proceeds via anionic (oxy anionic) or cationic mechanisms, depending on the catalyst; the anionic pathway, initiated by alkoxides under basic conditions, yields well-defined chains with narrow polydispersity due to its living character, while cationic mechanisms under acidic conditions can introduce branching but are less common for linear PEG 400. Control of the molecular weight in PEG 400 synthesis is primarily achieved by adjusting the , with an excess of water relative to ensuring the low required. Reaction conditions, such as short reaction times or low concentrations, further contribute to limiting growth and obtaining the target low molecular weight, resulting in a of chain lengths characteristic of living polymerizations. Following polymerization, purification involves the removal of unreacted , which is accomplished through to ensure residual levels below regulatory limits. The catalyst is then neutralized, typically by with an such as acetic acid for basic catalysts, followed by or to isolate the product.

Commercial Production

PEG 400 is commercially produced through the anionic of , a key raw material derived from the of sourced from petroleum refining processes, with or serving as the initiator to control the and achieve the desired average molecular weight of approximately 400 Da. This process occurs on an industrial scale in specialized reactors designed to handle the reactive and volatile nature of safely. The manufacturing typically employs either batch or continuous methods under elevated temperatures of 120–140°C and pressures to facilitate the exothermic , ensuring efficient conversion while minimizing side reactions. Major global producers include The Dow Chemical Company and , which operate large-scale facilities to meet demand across pharmaceutical, cosmetic, and industrial sectors. Global production of glycols, including PEG 400, surpassed 450,000 metric tons in 2024, with PEG 400 comprising a notable portion due to its widespread use; the process is energy-intensive primarily owing to the requirements for high-pressure containment and thermal management of the . in commercial production rigorously adheres to pharmacopeial standards to limit residual impurities from the synthesis, such as unreacted (not more than 10 ppm per USP, 1 ppm per EP) and the byproduct (not more than 10 ppm per both USP and EP), achieved through vacuum stripping and purification steps followed by analytical verification using .

Applications

Pharmaceutical Applications

PEG 400 functions as a key excipient in pharmaceutical formulations, primarily serving as a solvent and solubilizer for active pharmaceutical ingredients (APIs) with poor water solubility. Its high hydrophilicity and miscibility with water and organic solvents enable it to dissolve drugs effectively in various dosage forms, including oral liquids, injectables, and soft gelatin capsules, thereby enhancing drug stability and bioavailability. According to the FDA Inactive Ingredient Database, PEG 400 is approved for oral administration in forms such as capsules, elixirs, solutions, suspensions, and syrups, with maximum potencies ranging from 4.4 mg to 324.5 mg per unit dose and up to 1378 mg daily exposure. For example, in ibuprofen syrup formulations, PEG 400 is combined with other cosolvents like propylene glycol at concentrations up to 40% w/v to achieve complete solubilization of the API, facilitating uniform drug delivery in pediatric and adult oral suspensions. In parenteral applications, PEG 400 acts as a solubilizing agent in intramuscular and intravenous injections, where it is permitted at concentrations up to 18-20.3% v/v or 75.58% w/v, equivalent to a maximum of 7470 mg per dose. This use supports the formulation of injectable solutions for APIs requiring enhanced , such as in or preparations, while maintaining low profiles suitable for . Additionally, PEG 400 contributes indirectly to the efficacy of PEGylated therapeutics—where higher molecular weight PEGs are conjugated to proteins or drugs—by serving as an that improves overall formulation stability and API dispersion without altering the conjugation chemistry itself. As a vehicle in topical and ophthalmic products, PEG 400 provides modification and , forming the base for ointments, creams, and . In ophthalmic solutions, it is approved at up to 4% w/w, as seen in artificial tear formulations like Systane Ultra, where 0.4% PEG 400 combines with to relieve dry eye symptoms by augmenting tear film stability and reducing irritation. For topical creams and gels, concentrations up to 7.5% are utilized to enhance penetration and moisturization. PEG 400 is also included in formulations at lower doses than higher molecular weight PEGs (e.g., PEG 3350), acting as a to improve consistency and mild osmotic effects in oral suspensions or soft capsules. Studies demonstrate that PEG 400 can boost oral of certain BCS Class III drugs, such as and , by 34% or more through mechanisms involving increased gastrointestinal absorption and reduced efflux transporter activity. Overall, PEG 400's approval in numerous FDA New Drug Applications underscores its safety and versatility as an inactive ingredient across , with oral solutions commonly incorporating up to 30% to optimize API dissolution while adhering to regulatory limits.

Cosmetic and Personal Care Applications

PEG 400 serves as a versatile in cosmetic and personal care formulations, primarily functioning as a to attract and retain moisture in the and hair, thereby preventing dryness in products such as creams, lotions, and shampoos. In moisturizers, it is typically incorporated at concentrations of 5-10% to enhance hydration without compromising texture, leveraging its water-binding properties to maintain skin suppleness during application. This hygroscopic quality, derived from its polymeric structure, allows PEG 400 to absorb atmospheric moisture, making it ideal for daily items like body washes and facial cleansers where sustained moisture is essential. As an emulsifier and solubilizer, PEG 400 stabilizes oil-in-water mixtures in emulsions, ensuring uniform distribution of ingredients in formulations like soaps and , while also dissolving lipophilic components such as fragrances and essential oils that would otherwise separate. Concentrations in these products generally range from 1-20%, promoting better spreadability and a non-greasy feel upon application. In hair conditioners, it aids detangling by coating strands and reducing friction, often at 1-5% to improve manageability without residue buildup. In deodorants, PEG 400 acts as a carrier for active agents, facilitating even application and enhancing product in underarm products at levels around 1-3%. Similarly, in lip care formulations like balms, it contributes to smoothness by solubilizing waxes and oils, typically at low concentrations to provide a lightweight, hydrating layer on the s. Overall, these roles enable PEG 400 to improve sensory attributes across and items, from shampoos to emollients, at usage levels of 1-20% depending on the desired and stability.

Industrial Applications

PEG 400 serves as a versatile and in various industrial processes, enhancing flexibility and processability in materials such as inks, , and rubber compounds. In inks, it functions as a , , , and carrier, preventing and improving flow . For rubber production, PEG 400 acts as a mold-release agent and for both natural and synthetic rubbers, facilitating easier demolding while being readily removable with . In formulations, particularly and types, it improves plasticity and dispersibility, aiding in the creation of flexible coatings. In the , PEG 400 ( molecular weights 200-9,500) is approved for use as a direct under 21 CFR 172.820 for purposes such as a binder, plasticizing agent, , and adjuvant, and as a component of defoaming agents in processing under 21 CFR 173.340, in amounts not exceeding those reasonably required for the intended technical effect. Its low toxicity and solubility properties make it suitable for these roles without altering . Beyond these, PEG 400 finds application as a carrier and in and formulations, where its nature helps reduce dusting and improve solubility of active ingredients. It also serves as a in processing to maintain levels, and as a viscosity modifier in paints, acting as a binder, , and flow enhancer in water-based and formulations to optimize application consistency. Overall, PEG 400's industrial consumption in non-pharmaceutical sectors, including and related applications, reaches thousands of tons annually, underscoring its scale in . Its moderate contributes to these roles by providing effective without excessive thickening.

Safety and Regulations

Toxicity Profile

PEG 400 exhibits low , with an oral LD50 greater than 30 g/kg in rats, indicating minimal risk from single high exposures. It causes minimal and eye and is non-sensitizing in standard dermal tests. In chronic exposure studies, PEG 400 shows no evidence of carcinogenicity or across standard animal models, including rats and rabbits. At high oral doses exceeding 10 g/day, it may induce gastrointestinal effects such as and , though these are reversible and primarily osmotic in nature. PEG 400 is metabolized minimally and rapidly excreted unchanged, primarily in , with approximately 40-50% recovery within 24 hours following in animal and studies. Its high hydrophilicity prevents , as it does not bind to tissues and is efficiently cleared via renal pathways. Potential risks from impurities in PEG 400 include residual , a known , and , classified as likely carcinogenic to humans if present above controlled levels. These contaminants arise from the manufacturing process and must be minimized to ensure safety. Potential risks also include and , limited to not more than 0.25% combined per USP/NF for PEG 400, with enhanced testing mandated following 2023 FDA alerts on contaminated PEG excipients.

Regulatory Approvals

Polyethylene glycol 400 (PEG 400) is recognized by the U.S. (FDA) as (GRAS) for use as a direct under 21 CFR 172.820, permitting its incorporation in products at levels consistent with good practices. Additionally, PEG 400 is included in the FDA's Inactive Ingredient Database as an approved pharmaceutical for various routes of administration, including oral and topical formulations, with reported maximum concentrations up to 40% in approved drug products to ensure safety and efficacy. In the , PEG 400 is authorized for use in cosmetic products under Regulation (EC) No 1223/2009, listed in the CosIng database as a without a specific maximum concentration limit in Annex III, but subject to stringent purity requirements to minimize impurities such as and . Under the REACH regulation (EC) No 1907/2006, PEG 400 is registered (EC number 500-038-2) and does not qualify as a (SVHC), supporting its widespread industrial and consumer applications. The (WHO) acknowledges PEG 400 as an acceptable in pharmaceutical formulations through its technical reports and alignment with international pharmacopeial standards, facilitating its inclusion in where low inherent toxicity enables safe use in oral and topical preparations. The /National Formulary (USP/NF) provides a dedicated for Polyethylene Glycol 400, mandating purity specifications such as not exceeding 5 ppm and average molecular weight between 380 and 420 to ensure compliance in medicinal products. As of 2025, global pharmacopeias impose strict limits on residual impurities in PEG 400 to mitigate potential risks, including ethylene oxide not exceeding 10 μg/g (10 ppm) per USP/NF and 1 ppm per European Pharmacopoeia, and 1,4-dioxane not exceeding 10 ppm across major standards like USP/NF and ICH guidelines, with recent enhancements to EG/DEG testing per USP-NF (April 2025) and Ph. Eur. (effective January 2025). These thresholds require labeling disclosures and testing protocols during manufacturing to verify compliance, reflecting harmonized regulatory efforts for safe excipient use.

References

  1. https://www.sciencedirect.com/topics/[neuroscience](/page/Neuroscience)/polyethylene-glycol
Add your contribution
Related Hubs
User Avatar
No comments yet.